# Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC

> **NCT07038629** · PHASE2 · RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 52 (estimated)

## Conditions studied

- Esophageal Cancer

## Interventions

- **DRUG:** S1
- **DRUG:** Iparomlimab
- **RADIATION:** Radiation

## Key facts

- **NCT ID:** NCT07038629
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-01
- **Primary completion:** 2026-09-30
- **Final completion:** 2027-09-30
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2026-01-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07038629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07038629, "Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07038629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*